CN115066616A - 非酒精性脂肪性肝炎(nash)生物标志物及其用途 - Google Patents

非酒精性脂肪性肝炎(nash)生物标志物及其用途 Download PDF

Info

Publication number
CN115066616A
CN115066616A CN202180012807.5A CN202180012807A CN115066616A CN 115066616 A CN115066616 A CN 115066616A CN 202180012807 A CN202180012807 A CN 202180012807A CN 115066616 A CN115066616 A CN 115066616A
Authority
CN
China
Prior art keywords
subject
nash
biomarker
treatment
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180012807.5A
Other languages
English (en)
Chinese (zh)
Inventor
莉·亚历山大
瑞秋·奥斯多夫
斯图尔特·菲尔德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Private Placement Protein Body Operation Co ltd
Original Assignee
Private Placement Protein Body Operation Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Private Placement Protein Body Operation Co ltd filed Critical Private Placement Protein Body Operation Co ltd
Publication of CN115066616A publication Critical patent/CN115066616A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180012807.5A 2020-02-10 2021-02-09 非酒精性脂肪性肝炎(nash)生物标志物及其用途 Pending CN115066616A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062972418P 2020-02-10 2020-02-10
US62/972,418 2020-02-10
PCT/US2021/017217 WO2021163034A1 (en) 2020-02-10 2021-02-09 Nonalcoholic steatohepatitis (nash) biomarkers and uses thereof

Publications (1)

Publication Number Publication Date
CN115066616A true CN115066616A (zh) 2022-09-16

Family

ID=74858782

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180012807.5A Pending CN115066616A (zh) 2020-02-10 2021-02-09 非酒精性脂肪性肝炎(nash)生物标志物及其用途

Country Status (12)

Country Link
US (1) US20230071234A1 (https=)
EP (1) EP4103948A1 (https=)
JP (2) JP7766605B2 (https=)
KR (1) KR20220140727A (https=)
CN (1) CN115066616A (https=)
AU (1) AU2021220787A1 (https=)
BR (1) BR112022015303A2 (https=)
CA (2) CA3300793A1 (https=)
IL (1) IL295064A (https=)
MX (1) MX2022009517A (https=)
PH (1) PH12022552003A1 (https=)
WO (1) WO2021163034A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023238881A1 (ja) * 2022-06-07 2023-12-14 日東電工株式会社 非アルコール性脂肪性肝疾患（ｎａｆｌｄ）または非アルコール性脂肪肝炎（ｎａｓｈ）を診断するためのマーカー
WO2025090996A1 (en) * 2023-10-28 2025-05-01 Novelna Inc. Nafld detection proteins and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110143375A1 (en) * 2008-08-11 2011-06-16 Banyan Blomakers, Inc. Biomarker detection process and assay of neurological condition
US20160320395A1 (en) * 2013-11-13 2016-11-03 Electrophoretics Limited Materials and methods for diagnosis and prognosis of liver cancer
US20170016919A1 (en) * 2014-02-27 2017-01-19 Biogen Ma Inc. Method of assessing risk of pml
US20180259533A1 (en) * 2015-09-09 2018-09-13 Somalogic, Inc. Methods for developing personalized drug treatment plans and targeted drug development based on proteomic profiles
CN108603887A (zh) * 2016-02-08 2018-09-28 私募蛋白质体公司 非酒精性脂肪肝疾病(nafld)和非酒精性脂肪性肝炎(nash)生物标记及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US6001577A (en) 1998-06-08 1999-12-14 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US6458539B1 (en) 1993-09-17 2002-10-01 Somalogic, Inc. Photoselection of nucleic acid ligands
US6242246B1 (en) 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
US7855054B2 (en) 2007-01-16 2010-12-21 Somalogic, Inc. Multiplexed analyses of test samples
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US7824871B2 (en) * 2007-06-14 2010-11-02 George Mason Intellectual Properties Methods of diagnosing non-alcoholic steatohepatitis (NASH)
CN101802225B (zh) 2007-07-17 2013-10-30 私募蛋白质体公司 检测样品的多元分析
SG186953A1 (en) 2010-07-09 2013-02-28 Somalogic Inc Lung cancer biomarkers and uses thereof
CN103429753A (zh) 2010-09-27 2013-12-04 私募蛋白质体公司 间皮瘤生物标记及其用途
WO2014150198A2 (en) * 2013-03-15 2014-09-25 Somalogic, Inc. Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
CA2978696A1 (en) * 2015-02-03 2016-08-11 The Trustees Of The University Of Pennsylvania Novel methods for early identification of bone healing ability in injured patients
EP3303629A1 (en) * 2015-06-05 2018-04-11 Regulus Therapeutics Inc. Non-alcoholic fatty liver disease biomarkers
KR20180029046A (ko) * 2015-06-19 2018-03-19 세라 프로그노스틱스 인코포레이티드 조산 예측용 바이오마커 쌍
US9725769B1 (en) * 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
CN111183360B (zh) * 2017-07-19 2024-10-18 生物辐射欧洲有限公司 同时评估非酒精性脂肪性肝炎和肝纤维化状态的生物标志物组合

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110143375A1 (en) * 2008-08-11 2011-06-16 Banyan Blomakers, Inc. Biomarker detection process and assay of neurological condition
US20160320395A1 (en) * 2013-11-13 2016-11-03 Electrophoretics Limited Materials and methods for diagnosis and prognosis of liver cancer
US20170016919A1 (en) * 2014-02-27 2017-01-19 Biogen Ma Inc. Method of assessing risk of pml
US20180259533A1 (en) * 2015-09-09 2018-09-13 Somalogic, Inc. Methods for developing personalized drug treatment plans and targeted drug development based on proteomic profiles
CN108603887A (zh) * 2016-02-08 2018-09-28 私募蛋白质体公司 非酒精性脂肪肝疾病(nafld)和非酒精性脂肪性肝炎(nash)生物标记及其用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SILVA, R. N. ET AL: "ffect of physical training on liver expression of activin A and follistatin in a nonalcoholic fatty liver disease model in rats", 《BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH》, vol. 47, no. 9, 30 September 2014 (2014-09-30), pages 746 - 752, XP055446053, DOI: 10.1590/1414-431X20143869 *
TANAKA A: "Genetic association of Fc receptor-like 3 polymorphisms with susceptibility to primary biliary cirrhosis: ethnic comparative study in Japanese and Italian patients", 《TISSUE ANTIGENS》, vol. 77, no. 3, 31 March 2011 (2011-03-31), pages 239 - 243 *

Also Published As

Publication number Publication date
CA3166923A1 (en) 2021-08-19
JP2023512701A (ja) 2023-03-28
IL295064A (en) 2022-09-01
US20230071234A1 (en) 2023-03-09
KR20220140727A (ko) 2022-10-18
PH12022552003A1 (en) 2024-02-05
AU2021220787A1 (en) 2022-09-01
BR112022015303A2 (pt) 2022-09-27
JP2026021411A (ja) 2026-02-10
WO2021163034A1 (en) 2021-08-19
EP4103948A1 (en) 2022-12-21
CA3300793A1 (en) 2026-03-02
MX2022009517A (es) 2022-09-02
JP7766605B2 (ja) 2025-11-10

Similar Documents

Publication Publication Date Title
CN108957006B (zh) 非酒精性脂肪肝疾病(nafld)和非酒精性脂肪性肝炎(nash)生物标记及其用途
CN116008563B (zh) 非酒精性脂肪肝疾病(nafld)和非酒精性脂肪性肝炎(nash)生物标记及其用途
JP2026021411A (ja) 非アルコール性脂肪性肝炎（ｎａｓｈ）のバイオマーカー及びその使用
JP2025118715A (ja) 心血管リスク／イベントの予測及びその使用
WO2015153860A1 (en) Glomerular filtration rate biomarkers and uses thereof
JP7792338B2 (ja) 耐糖能異常障害を決定する方法
HK40078108A (en) Nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
HK40074269A (en) Methods of determining impaired glucose tolerance
JP2025526256A (ja) 試料品質評価の方法
HK40090190A (zh) 非酒精性脂肪肝疾病(nafld)和非酒精性脂肪性肝炎(nash)生物标记及其用途
CN118805086A (zh) 用于样品质量评估的方法
JP2023546563A (ja) 心血管イベントリスクの予測
HK40078070A (zh) 心血管风险事件预测及其用途
HK1259917A1 (en) Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
HK1259917B (en) Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof
HK1246853B (en) Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40078108

Country of ref document: HK